Citius Oncology Inc. Common Stock (CTOR)

FairStock Score: 54/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look first for an understandable business with durable economics. Citius Oncology is a targeted-oncology company, with LYMPHIR for relapsed or refractory cutaneous T-cell lymphoma. The mission is worthy, but the financial record shown here is not that of a mature franchise. In fiscal Q3 2026, the quarter ended 2026-06-30, revenue was $1.5M and net income was -$8.9M. Fiscal Q2 2026 revenue was $1.7M with a -$26.6M net loss, and fiscal Q1 2026 revenue was $3.9M with a -$5.5M loss. FY2025 net loss was -$24.8M; FY2024 was -$21.1M; only FY2022 shows a small profit of $380,811. That is not a record of consistent earning power. FairStock's calculated price at the 2026-10-26 close is $0.60; it shows P/E -1.24, P/B 1.57, ROE -126.58%, ROCE -29.12%, TTM FCF -$32.1M and FCF yield -58.0%. The Piotroski F-score of 3/9 and Altman Z-score of -1.28 suggest weak financial strength, while debt/equity of 0.25 is not the main problem; cash burn is. A beta of 3.53 tells me the shares are highly volatile. The Lynch category is TURNAROUND—loss in latest year after earlier profits—but turnarounds require evidence of improving economics, not just a low price. I see no clear moat yet: revenue is small relative to losses, margins are deeply negative, and growth data are not meaningful. At $0.60 and a $55.4M market cap, the price may look low, but without positive cash flow or durable earnings, Graham-style margin of safety is not evident.

In plain English: Citius Oncology develops and sells targeted cancer treatments, including LYMPHIR for a rare lymphoma. The business looks weak right now: it is losing money, using up cash, and has very little revenue. The share price looks low, but because profits are negative it is hard to call it cheap on earnings; it looks more like a risky turnaround.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-26 close · note generated 2026-10-28 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q3 2026 10-Q (period ended 2026-06-30) · fiscal Q2 2026 10-Q (period ended 2026-03-31) · fiscal Q1 2026 10-Q (period ended 2025-12-31) · fiscal Q3 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-09-30) · FY2024 10-K (period ended 2024-09-30) · FY2022 10-K (period ended 2022-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer